Clinical and immunomodulatory effects of repetitive 2-day cycles of high-dose continuous infusion IL-2

European Journal of Cancer Part A

Volumn 33, Issue 7, 1997, Pages 1050-1054

  Engelhardt, M ^a   Wirth, K ^a   Mertelsmann, R ^a   Lindemann, A ^a   Brennscheidt, U ^b  

^a UNIVERSITY OF FREIBURG   (Germany)

^b Parke Davis GmbH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

GAMMA INTERFERON; INTERLEUKIN 2; INTERLEUKIN 5; INTERLEUKIN 8; LYMPHOTOXIN; TUMOR NECROSIS FACTOR ALPHA;

ADULT; ANTINEOPLASTIC ACTIVITY; ARTICLE; CLINICAL ARTICLE; CONTINUOUS INFUSION; DOSE TIME EFFECT RELATION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOMODULATION; KIDNEY CARCINOMA; LYMPHOKINE ACTIVATED KILLER CELL; MALE; NATURAL KILLER CELL; PRIORITY JOURNAL; T LYMPHOCYTE ACTIVATION;

ADULT; ANTINEOPLASTIC AGENTS; BLOOD CELL COUNT; CARCINOMA, RENAL CELL; CYTOKINES; HUMANS; INFUSIONS, INTRAVENOUS; INTERLEUKIN-2; KIDNEY NEOPLASMS; KILLER CELLS, NATURAL; LYMPHOCYTE SUBSETS; MELANOMA; MIDDLE AGED; REMISSION INDUCTION; T-LYMPHOCYTE SUBSETS;

EID: 0030798810     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0959-8049(96)00530-8     Document Type: Article

References (15)

1. Schwartzentruber DJ. Biological therapy with interleukin-2: clinical applications. In DeVita VT, Hellman S, Rosenberg SA, eds. Biological Therapy of Cancer, 2nd ed. Philadelphia, PA, Lippincott JB, 1995. 235-269.
2. Rosenberg SA, Lotze MT, Muul LM, et al. A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated cells and interleukin-2 or high-dose interleukin-2 alone. New Engl J Med 1987, 316, 889-879.
3. West WH, Tauer KW, Yanelli J, et al. Constant infusion recombinant interleukin-2 in adoptive immunotherapy of cancer. New Engl J Med 1987, 316, 898-905.
4. Lindemann A, Höffken K, Schmidt RE, et al. A phase-II study of low-dose cyclophosphamide and recombinant human interleukin-2 in metastastic renal cell carcinoma and malignant melanoma. Cancer Immunother 1989, 28, 275-281.
5. Lindemann A, Brossart P, Höffken K, et al. Immunomodulatory effects of ultra-low-dose interleukin-2 in cancer patients: a phase Ib study. Cancer Immunol Immunother 1993, 37, 307-315.
6. Rosenberg SA, Packard BS, Aebersold PM, et al. Use of tumor-infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma. A preliminary report. New Engl J Med 1988, 319, 1676-1680.
7. Budd GT, Murthy S, Finke J, et al. Phase I trial of high-dose bolus IL-2 and interferon-alpha-2a in patients with metastatic malignancy. J Clin Oncol 1992, 10, 804-809.
8. Escudier B, Farace F, Angevin E, et al. Combination of interleukin-2 and gamma interferon in metastatic renal cell carcinoma . Eur J Cancer 1993, 5, 724-728.
9. Escudier B, Farace F, Angevin E, et al. Immunotherapy with interleukin-2 and lymphokine-activated natural killer cells: improvement of clinical responses in metastastic renal cell carcinoma patients previously treated with IL-2. Eur J Cancer 1994, 8, 1078-1083.
10. Negrier S, Philip T, Stoter G, et al. Interleukin-2 with or without LAK cells in metastatic renal cell carcinoma: a report of a European multicenter study. Eur J Cancer Clin Oncol 1989, 25, S21-S28.
11. Rosenberg SA, Yang JC, Topalian SL, et al. Treatment of 283 consecutive patients with metastatic melanoma or renal cell cancer using high-dose bolus interleukin-2. JAMA 1994, 271, 907-913.
12. Fyfe G, Fisher RI, Rosenberg SA, Sznol M, Parkinson DR, Louie AC. Results of treatment of 255 patients with metastatic renal cell carcinoma who received high-dose recombinant interleukin-2 therapy. J Clin Oncol 1995, 3, 688-696.
13. Lotze MT, Matory YL, Ettinghausen SE, et al. In vivo administration of purified human interleukin-2. II. Half-life, immunologic effects, and expansion of peripheral lymphoid cells in vivo with recombinant IL-2. J Immunol 1985, 135, 2865-2875.
14. Taga K, Mostowski H, Tosato G. Human interleukin-10 can directly inhibit T-cell growth. Blood 1993, 11, 2964-2971.
15. Goldman M. Interleukin-10 production during septicaemia. Lancet 1994, 343, 707-708.